{"analyses":[{"ciLowerLimit":"0.53","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.14","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.18","paramType":"Hazard Ratio (HR)","paramValue":"0.77","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"61"}],"title":"Death"},{"measurements":[{"groupId":"OG000","value":"116"},{"groupId":"OG001","value":"105"}],"title":"Alive"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"166"},{"groupId":"OG001","value":"166"}],"units":"Participants"}],"description":"Number of patients died from any cause during the study.","groups":[{"description":"Patients receive oral thalidomide daily and oral prednisone every other day for 4 years in the absence of disease progression or unacceptable toxicity.\n\nprednisone: Given orally\n\nthalidomide: Given orally","id":"OG000","title":"Prednisone"},{"description":"Patients undergo observation.","id":"OG001","title":"Observation"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Intention-to-treat population","reportingStatus":"POSTED","timeFrame":"9 years","title":"Overall Survival","type":"PRIMARY","unitOfMeasure":"Participants"}